ABSTRACT

Description: Lantus is a long-acting human insulin analogue (and appears to be identical to the product Optisulin). Lantus differs from natural human insulin at the Cterminal end of the B chain, which has two additional arginine residues, and at the C-terminus of the A chain, where asparagine residue number 21 is replaced by a glycine. Its overall molecular mass is 6,063 Da. Lantus is produced in modified Escherichia coli by recombinant DNA technology and is presented as a solution (100 IU/ml) for subcutaneous injection.